Moderna Inc. ($MRNA) Stock Forecast: Up 13.4% Today

What is Moderna Inc.?

Moderna (MRNA) experienced a significant increase in its stock value today, rising by 8.9%. The company is renowned for its mRNA pipeline, notably its Covid-19 vaccine.

Why is Moderna Inc. going up?

MRNA stock is up 13.4% on Mar 4, 2026 17:56

• Moderna's stock saw a notable rise following the resolution of patent disputes with Arbutus and Roivant, resulting in a settlement of up to $2.25 billion. This development brought clarity to Moderna's mRNA pipeline and eliminated a substantial financial risk.
• The settlement news generated optimism among investors regarding Moderna's forthcoming product innovations and potential revenue sources.
• Investor sentiment was positively influenced by the resolution of the legal issues, underscoring the importance of Moderna's capacity for innovation and product launches in sustaining long-term growth and success.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna and Ross Stores Lead Stock Gainers on Wednesday

Moderna (MRNA) and Ross Stores (ROST) were top stock gainers on Wednesday due to separate positive developments. Moderna's stock rose 8.9% after settling patent litigation with Arbutus and Roivant for up to $2.25 billion, clearing its mRNA pipeline. Ross Stores surged 6.6% premarket after beating Q4 earnings estimates, raising its dividend, and authorizing a new share repurchase program, driven by strong off-price retail performance.

https://247wallst.com/investing/2026/03/04/moderna-and-ross-stores-lead-stock-gainers-on-wednesday/

Prediction: Costco Will Surge After March 5th

Costco (COST) has seen a 17.03% increase year-to-date and is predicted to surge after its earnings report on March 5th. The company's strong performance is attributed to its high-margin membership fee income, accelerating e-commerce growth, and a consistent history of beating EPS estimates. Analysts maintain a positive outlook with a 12-month price target implying further upside, and the potential for a special dividend could act as an additional catalyst.

https://247wallst.com/investing/2026/03/04/prediction-costco-will-surge-after-march-5th/

Axsome Therapeutics, Inc. $AXSM Position Boosted by TD Asset Management Inc

TD Asset Management Inc. significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 107.7% in Q3, bringing its total to 44,192 shares valued at approximately $5.37 million. Other major institutions like Vanguard and Geode Capital Management also raised their holdings, contributing to institutional investors owning 81.49% of the company. Despite insider selling, Axsome outperformed quarterly revenue and EPS expectations, although it remains unprofitable.

https://www.marketbeat.com/instant-alerts/filing-axsome-therapeutics-inc-axsm-position-boosted-by-td-asset-management-inc-2026-03-04/

Moderna to pay about US$1 bil to settle Arbutus litigation

Moderna has agreed to pay US$950 million to settle all worldwide litigation with Arbutus Biopharma Corp and Genevant Sciences GmbH, resolving patent infringement claims related to the lipid nanoparticle technology used in its Covid-19 vaccine. This settlement removes a significant financial risk for Moderna, which had struggled to launch new products after the initial success of its vaccine. While Moderna's shares rose, Arbutus's fell, indicating investor disappointment regarding potential future payouts.

https://theedgemalaysia.com/node/794980

[Form 4] PROG Holdings, Inc. Insider Trading Activity

PROG Holdings, Inc.'s Chief Legal and Compliance Officer, Michael Todd King, reported two tax-withholding stock transactions in late February and early March 2026 related to vested restricted stock units. These transactions, coded as "F" on Form 4, involved the disposition of 2,775 shares at $35.21 and 2,663 shares at $33.56 to cover tax liabilities. Following these routine administrative actions, King directly holds 67,892 shares of the company's common stock.

https://www.stocktitan.net/sec-filings/PRG/form-4-prog-holdings-inc-insider-trading-activity-cab0657280b5.html

Trending Today

Bitcoin ($BTC) Crypto Forecast: Up 6.1% Today

Ethereum ($ETH) Crypto Forecast: Up 7.8% Today

Duolingo Inc. ($DUOL) Stock Forecast: Down 5.4% Today

Xerox Corporation ($XRX) Stock Forecast: Up 5.9% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.2% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Up 5.6% Today

Sonos Inc. ($SONO) Stock Forecast: Up 5.3% Today

Royal Caribbean Cruises Ltd. ($RCL) Stock Forecast: Down 5.3% Today

Roku Inc. ($ROKU) Stock Forecast: Up 5.0% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.5% Today

Moderna Inc. Price History

02.02.2026 - MRNA Stock was up 5.2%

• Moderna's stock saw an upward trajectory after receiving endorsement from the CHMP for its mCombriax COVID-19 and influenza combination vaccine. This favorable development, supported by promising Phase III study results, signifies a significant stride towards approval in the EU and potentially beyond.
• A price target increase by Piper Sandler for Moderna mirrors confidence in the company's vaccine portfolio, which includes upcoming milestones like the PDUFA date for the flu vaccine and Phase III melanoma data. Investors are reacting positively to the growth opportunities highlighted by Piper Sandler, despite ongoing safety concerns linked to mRNA technology.
• The positive trend in Moderna's stock stands in contrast to the challenges being tackled by other biotech firms such as Annovis Bio, CRISPR Therapeutics, and Alnylam Pharmaceuticals, as each navigates its distinct developments and regulatory environments.
• In summary, Moderna's bullish movement today is a result of favorable regulatory endorsements, advancements in its pipeline, and market enthusiasm surrounding its vaccine technologies, despite lingering safety considerations.

02.02.2026 - MRNA Stock was up 5.6%

• Moderna's stock rose after receiving a favorable opinion from the European Medicines Agency's drug review committee for its dual Covid-flu vaccine. This places Moderna at the forefront of the global competition for a combined vaccine.
• Concerns expressed by Pfizer's CEO regarding FDA leadership and internal disagreements on vaccine strategies may have indirectly benefitted Moderna, highlighting potential regulatory advantages for the company.
• Analysts have a positive view on Moderna's stock, increasing price targets and emphasizing its robust vaccine pipeline, contributing to investor confidence and the stock's upward movement.
• Moderna's strategic shift towards cancer and rare disease pipelines, in addition to potential regulatory approvals across various regions, showcases the company's diversification beyond Covid-19 vaccines, making it an appealing option for investors.

04.02.2026 - MRNA Stock was up 7.6%

• Following the announcement of a $950 million settlement to resolve patent infringement claims with Arbutus Biopharma Corp and Genevant Sciences GmbH, Moderna's stock saw a notable bullish trend.
• This settlement eliminated a significant financial risk for Moderna, increasing investor confidence in the company's future.
• Despite the substantial settlement, investors interpreted this news positively for Moderna, resulting in the bullish market movement.
• The information about the settlement overshadowed insider sales at Axsome Therapeutics and routine equity compensation activities at Molson Coors Beverage Co, underscoring the impact of legal resolutions on market sentiment.

20.01.2026 - MRNA Stock was up 8.3%

• The positive momentum in MRK stock could be linked to an upgraded Buy rating from Deutsche Bank with an increased price target. This optimistic forecast on the company's growth prospects, disregarding concerns about the Keytruda patent cliff, likely bolstered investor confidence.
• Furthermore, the FDA's approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication affirmed Merck's market position, underscoring its dedication to developing groundbreaking treatments.
• Ongoing patent disputes and legal conflicts in the biotech sector, like BioNTech's lawsuit against Moderna for patent infringement regarding COVID shots, may have impacted market sentiment towards established players such as Merck, potentially generating heightened interest and investment in the company's stock.

04.02.2026 - MRNA Stock was up 13.4%

• Moderna's stock saw a notable rise following the resolution of patent disputes with Arbutus and Roivant, resulting in a settlement of up to $2.25 billion. This development brought clarity to Moderna's mRNA pipeline and eliminated a substantial financial risk.
• The settlement news generated optimism among investors regarding Moderna's forthcoming product innovations and potential revenue sources.
• Investor sentiment was positively influenced by the resolution of the legal issues, underscoring the importance of Moderna's capacity for innovation and product launches in sustaining long-term growth and success.

23.01.2026 - MRNA Stock was up 6.0%

• Moderna experienced a strong bullish movement today due to multiple factors:
• Gilead Sciences' acquisition of Arcellx, focusing on CAR T-cell therapy, brought positive attention to the biotech sector and potentially increased investor confidence in similar companies like Moderna.
• The FDA's decision to review Moderna's mRNA flu vaccine and the initiation of the review for its investigational seasonal influenza vaccine submission (mRNA-1010) signaled progress and potential future revenue streams for the company.
• Despite facing legal challenges related to patent infringement and mixed financial results, including declining revenue, the positive developments with FDA reviews and vaccine submissions outweighed the concerns for investors.
• Telemark Asset Management LLC's significant acquisition of Moderna shares also indicated confidence in the company's future prospects, contributing to the bullish movement.

24.01.2026 - MRNA Stock was down 6.5%

• The bearish movement in MRNA's stock today is linked to concerns over potential FDA actions on mRNA vaccines, causing uncertainty and regulatory hurdles for the company's future vaccine developments.
• The negative revenue outlook and financial challenges may have led to investor caution and selling pressure on the stock.
• Despite recent positive updates, such as regulatory approvals and strategic agreements, the market sentiment appears to have been influenced more by broader challenges and uncertainties facing Moderna, resulting in the bearish movement in the stock today.

19.01.2026 - MRNA Stock was up 5.6%

• Merck & Co., Inc. (MRK) is a pharmaceutical company recognized for its innovative healthcare solutions. Today, the stock saw significant bullish movement in the market.
• MRK upgraded to a Buy rating by Deutsche Bank with a higher price target, noting undervaluation despite Keytruda patent cliff concerns.
• FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ for a new indication strengthened investor confidence in the company's growth prospects.
• Positive developments regarding MRK outshined worries about the Keytruda patent cliff, leading to the stock's bullish market movement.
• Investor optimism towards MRK's future growth prospects and product portfolio expansion drove the market's positive reaction.

25.01.2026 - MRNA Stock was up 5.6%

• Despite concerns about Moderna's financial standing, the stock has shown a notable recovery in its share price, signaling growing investor confidence.
• Positive outlook in the options market for Moderna, evident by the majority of trades predicting favorable outcomes, aligns with the current upward trend of the stock.
• Moderna's recent announcement about the FDA's review of its new mRNA flu vaccine, following dispute resolutions, likely contributed to the optimistic market sentiment and stock price surge.
• Protalix Biotherapeutics' strong performance, reaching a new 52-week high, reflects the overall robustness in the pharmaceuticals and biotechnology sector, potentially bolstering investor trust in companies like Moderna.

18.01.2026 - MRNA Stock was up 5.5%

• Optimism among investors was ignited by the FDA's decision to reassess Moderna's mRNA flu shot application after an initial rejection, potentially creating a new revenue source for the company.
• Despite uncertainties stemming from setbacks in the patent dispute with Arbutus Biopharma, investor focus on the flu vaccine review seemed to outweigh these concerns.
• Strong results from Moderna's combination flu/COVID vaccine trial further solidified investor confidence in the company's capabilities and future outlook, driving the bullish movement in stock price.
• Overall, market response to the FDA's review of Moderna's flu shot and encouraging vaccine trial outcomes indicates investor optimism about the company's ongoing success and innovation within the healthcare sector.

03.02.2026 - MRNA Stock was down 6.2%

• The decline in Moderna's stock today is possibly due to investors taking profits following a period of successful performance.
• Merck's notable revenue growth fueled by Keytruda, a competitor PD-1 inhibitor, might have sparked concerns about potential competition for Moderna in the immuno-oncology sector.
• The proposed stock offering by MAIA Biotechnology to finance trials could have affected Moderna's stock price, as investors may be wary of potential dilution in the biotech industry.
• Despite optimistic outlooks from analysts and advancements in its pipeline, general market sentiment regarding regulatory approvals and market acceptance of Moderna's mRNA-based vaccines may be influencing the stock's movements.

03.02.2026 - MRNA Stock was down 6.3%

• Analysts are bullish on Moderna, maintaining Buy ratings and positive price targets, indicating long-term growth potential.
• The transition to a more diversified business model, including RSV and flu vaccines, has garnered investor interest, but concerns remain regarding regulatory approvals and market adoption.
• The decline in Moderna's stock price could be attributed to the negative market reaction to MAIA Biotechnology's stock sale announcement, raising concerns about potential dilution for existing shareholders.
• Despite positive news of Moderna's dual Covid-flu vaccine nearing EMA approval, regulatory hurdles in the US for other vaccines and shifting focus to different pipelines may have contributed to the bearish market movement.